BioCentury
ARTICLE | Clinical News

Amylin starts Phase II diabetes study

November 2, 2000 8:00 AM UTC

AMLN began placebo-controlled Phase II testing of its AC2993 synthetic exendin-4 in more than 100 patients with Type II diabetes who are not achieving adequate blood glucose target levels with their o...